Background: ROS1 immunohistochemistry has become routine to triage NSCLC cases lacking EGFR and ALK alterations for subsequent FISH testing to determine patient eligibility for crizotinib therapy. We observed that, in the large majority of cases showing increased ROS1 expression, ROS1 rearrangements were not detected.